Irbesartan Bluepharma (Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding. This inhibition stops vasoconstriction and aldosterone release, leading to relaxed blood vessels, reduced sodium and water retention, and ultimately lower systemic blood pressure.

The dosage of Irbesartan Bluepharma is determined by the prescribing clinician based on the individual’s blood pressure, renal function, and overall health status. The prescriber will select an appropriate strength and titrate as needed, following local prescribing guidelines.

Irbesartan is classified as Pregnancy Category D, indicating evidence of risk to the fetus, and it should be avoided in the second and third trimesters. Limited data are available for breastfeeding; therefore, use is generally not recommended unless the potential benefit outweighs the risk.

To place an order, submit an enquiry on the Irbesartan Bluepharma product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with ACE inhibitors, Irbesartan offers similar blood‑pressure‑lowering effects but has a lower incidence of cough. Unlike calcium‑channel blockers, it directly blocks the renin‑angiotensin system, providing renal protective benefits especially in diabetic patients.

Irbesartan Bluepharma should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Do not freeze the product, and keep it out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by the healthcare professional. Swallow the tablet whole with a glass of water; do not split, crush or chew unless specifically instructed.

The most critical adverse events include angioedema, severe hyperkalemia, acute kidney injury and significant hypotension. Patients should be educated to seek immediate medical attention if they experience swelling of the face, lips or throat, marked weakness, or a sudden drop in blood pressure.

Irbesartan is contraindicated in patients with known hypersensitivity to the drug, in those with severe hepatic impairment, and in pregnant women during the second and third trimesters. Caution is also advised for individuals with bilateral renal artery stenosis or those taking multiple potassium‑raising agents.